---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-071084"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:19:54.713221+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports positive initial Phase 2 data for paltusotine in carcinoid syndrome; 65% symptom reduction

## Summary
- 65% reduction in excess bowel movements and 65% reduction in flushing frequency in evaluable patients.
- No treatment-related severe or serious adverse events; most AEs mild-to-moderate (diarrhea, headache, abdominal pain).
- 87% (13/15) of completers enrolled in long-term extension; study enrollment complete (N=36).
- Topline results from full Phase 2 study expected in first half of 2024.

## SEC filing metadata
- accession: 0000950170-23-071084
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017023071084/0000950170-23-071084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017023071084/crnx-20231218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-071084
- JSON: https://secwatch.observer/filing/0000950170-23-071084.json
- Plain text: https://secwatch.observer/filing/0000950170-23-071084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.